Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Figures & data

Table 1 Characteristics of the 317 Advanced SQ-NSCLC Patients Evaluated for Eligibility to Receive Anti-VEGF Therapy

Characteristic	Value
Age, median (range), years	68 (32–89)
Sex
Male	255 (80.4)
Female	62 (19.6)
ECOG PS (diagnosis)
0	94 (29.7)
1	166 (52.4)
≥2	46 (14.5)
Unknown	11 (3.5)
Smoking status
Smoker	160 (50.5)
Ex-smoker	138 (43.5)
Non-smoker	11 (3.5)
Unknown	8 (2.5)
Stage at diagnosis
Non-metastatic	110 (34.7)
IV	207 (65.3)
Number of metastatic sites
1	125 (60.4)
≥1	82 (39.4)
Metastatic site
Brain	25 (7.9)
Nodes	18 (5.7)
Lung	83 (26.2)
Liver	34 (10.7)
Adrenal gland	27 (8.5)
Bone	63 (19.9)
Skin	3 (0.9)
Other(s)	64 (20.2)

Note: Results are expressed as number (%), unless stated otherwise.

Abbreviations: SQ-NSCLC, squamous non-small–cell lung cancer; VEGF, vascular endothelial growth factor; ECOG PS, Eastern Cooperative Oncology Group performance status.

Table 2 Reasons for Ineligibility of Advanced SQ-NSCLC Patients to Receive Antiangiogenics*

Reason for Ineligibility	Number (%)
Extension to large blood vessels	105 (48.3)
Tumor with cavitation	54 (24.8)
Cardiovascular disease^†	29 (13.4)
Hemoptysis	19 (8.7)
Systemic inflammatory disease^‡	10 (4.6)

Notes: *Patients could have several ineligibility criteria (n=217). ^†Prior thromboembolic event(s), uncontrolled hypertension, etc. ^‡Hemorrhagic disorder, prior gastrointestinal perforation, systemic disease, inflammatory bowel disease, vasculitis.

Abbreviation: SQ-NSCLC, squamous non-small–cell lung cancer.

Figure 1 Flow chart of the study. Patients could have more than 1 ineligibility criterion.

Table 3 Percentages of Clinical Factors as a Function of Ineligibility Criteria

	Ineligibility Criterion
Clinical Factor	Extension to Large Vessels n=105	Cavitation n=54	Hemoptysis n=19	CV Diseases n=29
Men/women	81.9/18.1	77.8/22.2	89.5/10.5	93.1/6.9
Stage IV/others	65.7/34.3	75.9/24.1	63.2/36.8	72.4/27.6
>1/≤1 metastatic site(s)	60.9/39/1	65.9/34.1	58.3/41.7	71.4/28.6
1^st-line chemotherapy	99.1	100	94.7	100
ECOG PS: 0/1;2;≥2	30.7;55.4;13.9	28.3;52.8;18.9	31.6;47.4;21.1	17.9;67.9;14.3

Abbreviations: CV, cardiovascular; ECOG PS, Eastern Cooperative Oncology Group performance status.